{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:27:58Z","timestamp":1772580478884,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1053\/j.gastro.2022.06.076","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T01:56:52Z","timestamp":1656554212000},"page":"572-574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Current Role of Vonoprazan in Helicobacter pylori Treatment"],"prefix":"10.1053","volume":"163","author":[{"given":"Carlo A.","family":"Fallone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2022.06.076_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection \u2013 the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.06.076_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG Clinical Guideline: Treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.06.076_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto Consensus for the Treatment of Helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.06.076_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11938-020-00330-x","article-title":"Acid suppressant therapy: a step forward with potassium-competitive acid blockers","volume":"19","author":"Scarpignato","year":"2021","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1053\/j.gastro.2022.06.076_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1523-5378.2007.00508.x","article-title":"Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy","volume":"12","author":"Sugimoto","year":"2007","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2022.06.076_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9781212","article-title":"Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori Eradication: a meta-analysis of randomized clinical trials","volume":"2019","author":"Lyu","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1053\/j.gastro.2022.06.076_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12495","article-title":"Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori","volume":"23","author":"Li","year":"2018","journal-title":"Helicobacter"},{"key":"10.1053\/j.gastro.2022.06.076_bib8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the united states and Europe: randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.06.076_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2019.04.011","article-title":"Reconciliation of recent H.\u00a0pylori treatment guidelines in a time of increasing antibiotic resistance","volume":"157","author":"Fallone","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.06.076_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/gutjnl-2020-321372","article-title":"European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients","volume":"70","author":"Nyssen","year":"2021","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.06.076_bib11","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s10620-019-05694-4","article-title":"Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA","volume":"64","author":"Alsamman","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2022.06.076_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/pathogens10010015","article-title":"Rifabutin for the treatment of Helicobacter Pylori infection: a review","volume":"10","author":"Gisbert","year":"2021","journal-title":"Pathogens"},{"key":"10.1053\/j.gastro.2022.06.076_bib13","first-page":"1658","article-title":"Experience with rifabutin-containing therapy in 500 patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)","volume":"11","author":"Nyssen","year":"2022","journal-title":"J\u00a0Clin Med"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522007387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522007387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:36:23Z","timestamp":1758036983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508522007387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0016508522007387"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2022.06.076","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Current Role of Vonoprazan in Helicobacter pylori Treatment","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2022.06.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2022.05.055","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}